ArticleBMC infectious diseases2026
Epidemiology, antifungal susceptibility, risk factors, and mortality of adult candidemia at a tertiary hospital in Eastern China from 2020 to 2025.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood Stream Infections due toInternational journal of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThis study aimed to investigate the epidemiology, antifungal resistance profiles, and risk factors for 30-day mortality in adult patients with candidemia in Eastern China, ultimately informing improved clinical management strategies.
methodsData on clinical characteristics, blood culture isolates, and antifungal susceptibility were retrospectively collected from the laboratory information system and analyzed for adult patients with culture-confirmed candidemia from 2020 to 2025. Independent risk factors for 30-day mortality were identified using univariate and multivariate logistic regression analyses.
resultsA total of 111 candidemia cases were identified during the study period. Patients were predominantly male (68/111, 61.26%), with the largest proportion aged 60–74 years (44/111, 38.74%). Nearly half of all cases (51/111, 45.95%) were identified in the intensive care unit (ICU). Candida albicans was the most frequently isolated species (52/111, 46.85%), followed by Nakaseomyces glabratus (formerly Candida glabrata) (24/111, 21.62%), Candida parapsilosis (19/111, 17.12%), Candida tropicalis (15/111, 13.51%), and Pichia kudriavzevii (formerly Candida krusei) (1/111, 0.90%). No significant shift in species distribution was observed over the six-year period (P > 0.05). Antifungal susceptibility testing revealed that all isolates were susceptible to amphotericin B and 5-flucytosine. However, Candida tropicalis showed the highest resistance rates to voriconazole (9/15, 60.00%) and fluconazole (7/15, 46.67%). Resistance in Candida albicans was notable for itraconazole (8/52, 15.38%). The overall 30-day mortality rate was 43.24% (48/111). On multivariate analysis, cardiac disease was an independent risk factor for mortality (adjusted OR = 3.27, 95% CI: 1.36–7.88, P = 0.008).
conclusionAdult Candidemia was associated with high mortality in Suzhou, China. Although Candida albicans remained predominant, the clinical burden of non-albicans species and high local resistance, especially to voriconazole in Candida tropicalis, underscored the necessity of targeted therapy. Cardiac disease was an independent predictor of mortality, emphasizing the importance of cardiovascular risk assessment, particularly in the elderly.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.